Clinical Utility of Procalcitonin in The Prediction of Cardiovascular Complications in Patients with Type 2 Diabetes Mellitus

Objective:this study was initiated to assess procalcitoninas prognostic marker forcardiovascular complication in type2 diabetic patients. Subjects and methods:forty  type 2 diabetic patients without cardiovascular disease, forty  type 2 diabetic patients with cardiovascular disease and twenty healthy control counterparts were included in the present study. Serum procalcitoninlevels were assayed and correlated with metabolic parameters.ROC curve analysis was also done for this biochemical marker. Results:the mean level of procalcitonin was 707.17± 99.19ng/l in diabetic subjects versus 881.30± 123.56ng/l for the cardio-diabetic subjects (P < 0.0001).Procalcitonin levels were significantly amplified in the cardio-diabetic patients with increasing C-reactive protein (CRP), triglycerides (TG), fasting blood glucose (FBG),and cholesterol (P = 0.004, 0.0005, 0.002 and 0.01 respectively). From ROC curve analysis, it was observed that the area under curve for procalcitoninwas 0.878. This finding indicates the good validity of the above biomarker as aprognostic factor for cardiovascular complication in type 2 diabetic patients. Conclusion:this study evidences the usefulness of measuring serum levels of procalcitoninin diagnosis of cardiovascular complication in type 2 diabetic patients.